Материал: БА 2021-2022

Клинические рекомендации – Бронхиальная астма – 2021-2022-2023 (23.06.2021) – Утверждены Минздравом РФ

count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med. 2015 Nov; 3(11): 849 – 58.

21.Albers FC, Licskai C, Chanez P, Bratton DJ, Bradford ES, Yancey SW, Kwon N, Quirce S. Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma. Respir Med. 2019 Nov; 159: 105806.

22.Bush A. Management of asthma in children. Minerva Pediatr. 2018 Oct; 70(5): 444-457.

23.Rath N, Raje N, Rosenwasser L. Immunoglobulin E as a Biomarker in Asthma. Immunol Allergy Clin North Am. 2018 Nov; 38(4): 587-597.

24.Ahlstedt S., Murray C.S. In vitro diagnosis of allergy: how to interpret IgE antibody results in clinical practice. Prim Care Respir J 2006; 15: 228 – 36.

25.Miller M.R., Hankinson J., Brusasco V., et al. Standardisation of spirometry. Eur Respir J 2005;

26:319 – 38.

26.Levy M.L., Quanjer P.H., Booker R., et al. Diagnostic spirometry in primary care: Proposed standards for general practice compliant with American Thoracic Society and European Respiratory Society recommendations: a General Practice Airways Group (GPIAG) document, in association with the Association for Respiratory Technology & Physiology (ARTP) and Education for Health. Prim Care Respir J 2009; 18: 130 – 47.

27.Методические рекомендации по использованию метода спирометрии. Российское респираторное общество. Утверждены Минздравом России в 2016 г. – М., – 2016 – 36 с.: 6-7.

28.Pellegrino R., Viegi G., Brusasco V., et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26: 948 – 68.

29.Tan W.C., Vollmer W.M., Lamprecht B., et al. Worldwide patterns of bronchodilator responsiveness: results from the Burden of Obstructive Lung Disease study. Thorax 2012; 67: 718 – 26.

30.Crapo R.O., Casaburi R., Coates A.L., et al. Guidelines for methacholine and exercise challenge testing-1999. Am J Respir Crit Care Med 2000; 161: 309 – 29.

31.Swartz E, Lang D. When should a methacholine challenge be ordered for a patient with suspected asthma? Cleve Clin J Med. 2008 Jan; 75(1): 37-40. doi: 10.3949/ccjm.75.1.37. PMID: 18236728.

32.Parsons J.P., Hallstrand T.S., Mastronarde J.G., et al. An official American Thoracic Society clinical practice guideline: exerciseinduced bronchoconstriction. Am J Respir Crit Care Med 2013; 187: 1016 – 27.

33.Reddel H.K., Taylor D.R., Bateman E.D., et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009; 180: 59-99.

34.Brouwer A.F., Brand P.L. Asthma education and monitoring: what has been shown to work. Paediatr Respir Rev 2008; 9: 193 – 9.

35.Beydon N, Davis SD, Lombardi E, Allen JL, Arets HG, Aurora P, Bisgaard H, Davis GM, Ducharme FM, Eigen H, Gappa M, Gaultier C, Gustafsson PM, Hall GL, Hantos Z, Healy et al.; American Thoracic Society/European Respiratory Society Working Group on Infant and Young Children Pulmonary Function Testing. An official American Thoracic Society/European Respiratory Society statement: pulmonary function testing in preschool children. Am J Respir Crit Care Med. 2007 Jun 15; 175(12): 1304 – 45.

36.Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, Hallstrand TS, Kaminsky DA, McCarthy K, McCormack MC, Oropez CE, Rosenfeld M, Stanojevic S, Swanney MP, Thompson BR. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory.

37.American Thoracic Society, European Respiratory Society. ATS/ERS Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide, 2005. Am J Respir Crit Care Med 2005; 171: 912 – 30.

38.Schleich F.N., Manise M., Sele J., Henket M., Seidel L., Louis R. Distribution of sputum

Клинические рекомендации – Бронхиальная астма – 2021-2022-2023 (23.06.2021) – Утверждены Минздравом РФ

cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulm Med. 2013 Feb 26; 13: 11. Doi: 10.1186/1471-2466-13-11.

39.Dweik R.A., Boggs P.B., Erzurum S.C., et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011; 184: 602 – 15. 2.

40.Malo J.L., Cote J., Cartier A. et al. How many times per day should peak expiratory flow rates be assessed when investigating occupational asthma? Thorax 1993; 48: 1211 – 17.

41.Baur X., Huber H., Degens P.O. et al. Relation between occupational asthma case history, bronchial methacholine challenge, and specific challenge test in patients with suspected occupational asthma. Am J Ind Med 1998; 33: 114 – 22.

42.Fishwick D., Barber C.M., Bradshaw L.M., Harris-Roberts J., Francis M. et al. Standards of care for occupational asthma. Thorax 2008 Mar; 63(3): 240 – 50.

43.Mapp C.E., Saetta M., Maestrelli P., Fabbri L. Occupational asthma. Eur Respir Monograph / Ed. By Mapp CE Occupational Lung Disorders 1999 V 4. Monograph 11. P. 255.

44.Bousquet J., Heinzerling L., Bachert C., Papadopoulos N.G., Bousquet P.J., Burney P.G., et al. Practical guide to skin prick tests in allergy to aeroallergens. Allergy 2012; 67: 18-24.

45.Ait-Khaled N., Enarson D.A., Chiang C.-Y., Marks G., Bissell K. Management of asthma: a guide to the essentials of good clinical practice. Paris, France: International Union Against Tuberculosis and Lung Disease; 2008. 4.

46.Papadopoulos NG, Arakawa H, Carlsen KH, Custovic A, Gern J, Lemanske R, et al. International consensus on (ICON) pediatric asthma. Allergy Eur J Allergy Clin Immunol. 2012; 67(8): 976-977.

47.Аллергология и иммуннология / Союз педиатров России – М.: Союз педиатров России,

2020. – 512 с.

48.Doherty G., Bush A. Diagnosing respiratory problems in young children. Practitioner 2007; 251:

20, 2-5.

49.Gibson P.G., Powell H., Coughlan J., et al. Self-management education and regular practitioner review for adults with asthma. Cochrane Database Syst Rev 2003: CD001117.

50.Fishwick D., D'Souza W., Beasley R. The asthma self-management plan system of care: what does it mean, how is it done, does it work, what models are available, what do patients want and who needs it? Patient Educ Couns 1997; 32: S21 – 33.

51.Ramnath V.R., Clark S., Camargo C.A., Jr. Multicenter study of clinical features of suddenonset versus slower-onset asthma exacerbations requiring hospitalization. Respir Care 2007; 52: 1013 – 20.

52.Geelhoed G.C., Landau L.I., Le Souef P.N. Evaluation of SaO2 as a predictor of outcome in 280 children presenting with acute asthma. Ann Emerg Med 1994; 23: 1236 – 41.

53.Atta J.A., Nunes M.P., Fonseca-Guedes C.H., et al. Patient and physician evaluation of the severity of acute asthma exacerbations. Braz J Med Biol Res 2004; 37: 1321 – 30.

54.Nowak R.M., Tomlanovich M.C., Sarkar D.D., Kvale P.A., Anderson J.A. Arterial blood gases and pulmonary function testing in acute bronchial asthma. Predicting patient outcomes. JAMA 1983; 249: 2043 – 6.

55.White C.S., Cole R.P., Lubetsky H.W., Austin J.H. Acute asthma. Admission chest radiography in hospitalized adult patients. Chest 1991; 100: 14 – 6.

56.Taylor D.R., Bateman E.D., Boulet L.P., et al. A new perspective on concepts of asthma severity and control. Eur Respir J 2008; 32: 545 – 54. \ Anonymous. Using beta 2-stimulants in asthma. Drug Ther Bull 1997; 35: 1 – 4.

57.O'Byrne P.M., FitzGerald M., Bateman E.D., et al. Inhaled combined budesonide-formoterol as needed in mild asthma [article and supplementary appendix]. N Engl J Med. 2018; 378: 1865-1876. https://dx.doi.org/doi10.1056/NEJMoa1715274. Accessed May 16, 2018.

58.Bateman E.D., Reddel H.K., O'Byrne P.M., et al. As-needed budesonide-formoterol versus

Клинические рекомендации – Бронхиальная астма – 2021-2022-2023 (23.06.2021) – Утверждены Минздравом РФ

maintenance budesonide in mild asthma [article and supplementary appendix]. N Engl J Med. 2018; 378: 1877-1887.

59.Papi A., Canonica G.W., Maestrelli P., Paggiaro P., Olivieri D., Pozzi E., Crimi N., Vignola A.M., Morelli P., Nicolini G., Fabbri L.M.; BEST Study Group. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med 2007; 356(20): 2040-2052.

60.Авдеев С.Н., Айсанов З.Р., Архипов В.В., Белевский А.С., Визель А.А., Демко И.В., Емельянов А.В., Ильина Н.И., Курбачева О.М., Лещенко И.В., Ненашева Н.М., Овчаренко С.И., Фассахов Р.С. от лица экспертной группы. Принципы выбора терапии для больных легкой бронхиальной астмой. Согласованные рекомендации РААКИ и РРО. Практическая пульмонология. 2017; 1: 44-54.

61.Pauwels R.A., Pedersen S., Busse W.W., et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 2003; 361: 1071 – 6.

62.O'Byrne P.M., Barnes P.J., Rodriguez-Roisin R., et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164(8 Pt 1): 1392 – 7.

63.Adams N.P., Bestall J.B., Malouf R., Lasserson T.J., Jones P.W. Inhaled beclomethasone versus placebo for chronic asthma. Cochrane Database Syst Rev 2005: CD002738.

64.Philip G., Nayak A.S., Berger W.E., et al. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr Med Res Opin 2004; 20: 1549 – 58.

65.Wilson A.M., Dempsey O.J., Sims E.J., Lipworth B.J. A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma. Clin Exp Allergy 2001; 31: 616 – 24.

66.Guevara J.P., Ducharme F.M., Keren R., Nihtianova S., Zorc J. Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma. Cochrane Database Syst Rev 2006: CD003558.

67.Bisgaard H., Zielen S., Garcia-Garcia M.L. et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma // Am. J. Respir. Crit. Care Med. 2005. Vol. 171. N 4. P. 315-322.

68.Matsuse H., Tsuchida T., Fukahori S. et al. Retrospective cohort study of leukotriene receptor antagonist therapy for preventing upper respiratory infection-induced acute asthma exacerbations // Allergy Rhinol. (Providence). 2013. Vol. 4. N 3. P. E127-131.

69.Ducharme F.M., Ni Chroinin M., Greenstone I., Lasserson T.J. Addition of long-acting beta2agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev 2010: CD005535.

70.Cates C.J., Karner C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database Syst Rev 2013; 4: CD007313.

71.Papi A., Corradi M., Pigeon-Francisco C., et al. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. Lancet Respir Med 2013; 1: 23-31.

72.Patel M., Pilcher J., Pritchard A., et al. Efficacy and safety of maintenance and reliever combination budesonide/formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet Respir Med 2013; 1: 32-42.

73.Bateman E.D., Harrison T.W., Quirce S., et al. Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. Respir Res 2011; 12: 38.

74.Ni Chroinin M., Lasserson T.J., Greenstone I., Ducharme F.M. Addition of long-acting betaagonists to inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst Rev 2009: CD007949.

75.Vaessen-Verberne A.A., van den Berg N.J., van Nierop J.C., et al. Combination therapy salmeterol/fluticasone versus doubling dose of fluticasone in children with asthma. Am J Respir Crit Care Med 2010; 182: 1221 – 7.

Клинические рекомендации – Бронхиальная астма – 2021-2022-2023 (23.06.2021) – Утверждены Минздравом РФ

76.Peters S.P., Kunselman S.J., Icitovic N. et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma // N. Engl. J. Med. 2010. Vol. 363. N 18. P. 1715-1726.

77.Bateman ED, et al. Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J. Allergy Clin. Immunol. 2011; 128: 315-322. doi: 10.1016/j.jaci.2011.06.004.

78.Kerstjens HA, et al. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallelgroup, active-comparator, randomised trials. Lancet Respir. Med. 2015; 3: 367-376. doi: 10.1016/S22132600(15)00031-

79.Kew KM, Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination longacting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst Rev. 2016 Jan 21; (1): CD011721.

80.Rodrigo G.J., Neffen H. Efficacy and safety of tiotropium in school-age children with moderate- to-severe symptomatic asthma: A systematic review. Pediatr Allergy Immunol. 2017 Sep; 28(6): 573-578.

81.Rodrigo G.J., Castro-Rodriguez J.A. What is the role of tiotropium in asthma?; a systematic review with meta-analysis. Chest 2015; 147: 388 – 96.

82.Kerstjens H.A., Disse B., Schroder-Babo W., et al. Tiotropium improves lung function in patients with severe uncontrolled asthma: A randomized controlled trial J Allergy Clin Immunol 2011;

128:308-314.

83.Kerstjens H.A., Engel M., Dahl R. et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012; 367: 1198-1207.

85.Laurie A Lee, Zelie Bailes, Neil Barnes, Louis-Philippe Boulet, Dawn Edwards, Andrew Fowler, Nicola A Hanania, Huib A M Kerstjens, Edward Kerwin, Robert Nathan, John Oppenheimer, Alberto Papi, Steven Pascoe, Guy Brusselle, Guy Peachey, Neal Sule, Maggie Tabberer, Ian D Pavord Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial Lancet VOLUME 9, ISSUE 1, P 69-84, JANUARY 01, 2021.

86.O'Byrne P.M., Naya I.P., Kallen A., Postma D.S., Barnes P.J. Increasing doses of inhaled corticosteroids compared to adding long-acting inhaled beta2-agonists in achieving asthma control. Chest 2008; 134: 1192 – 9. 1.

87.Price D.B., Hernandez D., Magyar P., et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003;

58:211 – 6.

88.Vaquerizo M.J., Casan P., Castillo J., et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 2003; 58: 204 – 10.

89.Tamaoki J., Kondo M., Sakai N., et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group. Am J Respir Crit Care Med 1997; 155: 1235 – 40.

90.Rodrigo G.J., Neffen H., Castro-Rodriguez J.A. Efficacy and safety of subcutaneous omalizumab vs placebo as addon therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 2011; 139: 28-35.

91.Normansell R., Walker S., Milan S.J., Walters E.H., Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 2014; 1: CD003559.

92.Castro M., Zangrilli J., Wechsler M.E. et al. Reslizumab for inadequately controlledasthma with elevatedblood eosinophil counts: results from multicenter, parallel, double-blind, randomized, placebocontrolled, phase 3 trials. Lancet Respir Med 2015; 3: 355 – 66.

93.Pavord I.D., Korn S., Howarth P., et al. Mepolizumab for severe eosinophilic asthma

Клинические рекомендации – Бронхиальная астма – 2021-2022-2023 (23.06.2021) – Утверждены Минздравом РФ

(DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380: 651 – 9.

94.Ortega H.G., Liu M.C., Pavord I.D. et al. Mepolizumab treatment in patients with severe eosinophilic asthma // N. Engl. J. Med. 2014. Vol. 371. P. 1198-1207.

95.Bel E.H., Wenzel S.E., Thompson P.J. et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma // N. Engl. J. Med. 2014. Vol. 371. P. 1189-1197.

96.FitzGerald J.M., Bleecker E.R., Nair P. et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet 2016; 388: 2128 – 41.

97.Bleecker E.R., FitzGerald J.M., Chanez P. et al. Efficacy and safety of benralizumab for patients

(SIROCCO): a randomized, multi-centre, placebo-controlled phase 3 trial. Lancet 2016; 388: 2115 – 27.

98.Castro M., Corren J., Pavord I.D., et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018; 378(26): 2486-2496.

99.Rabe K.F. et al. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. N Engl J Med 2018; 378: 2475-2485.

100.Zayed Y. et al. Dupilumab safety and efficacy in uncontrolled asthma: a systematic review and meta-analysis of randomized clinical trials. J Asthma. 2018 Oct 1: 1-10.

101.Diagnosis and Management of Difficult-to-treat and Severe Asthma in adolescent and adult patients. A GINA pocket guide for health professionals. April 2019, v 2.0. Available on the www.ginasthma.org.

102.Chung K.F., Wenzel S.E., Brozek J.L., et al. International ERS/ATS Guidelines on Definition, Evaluation and Treatment of Severe Asthma. Eur Respir J 2014; 43: 343 – 73.

103.Rivington R.N., Boulet L.P., Cote J., et al. Efficacy of Uniphyl, salbutamol, and their combination in asthmatic patients on highdose inhaled steroids. Am J Respir Crit Care Med 1995; 151: 325 – 32.

104.Vogelberg C., Moroni-Zentgraf P., Lronaviciute-Klimantaviciene M., Sigmund R., Hamelmann E. et al. A randomized dose-ranging study of tiotropium Respimat in children with symptomatic asthma despite inhaled corticosteroids. Repir Res. 2015; 16(1): 20.

105.Guo J., Tsai K., Kelton C., Bian B., Wigle P. Risk of serious asthma exacerbations associated with long-acting beta agonists among patients with asthma: A retrospective cohort study. Ann Allergy Asthma Immunol 106: 214-222.

106.Melani A.S., Bonavia M., Cilenti V. et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med 2011; 105: 930 – 8.

107.Fink J.B., Rubin B.K. Problems with inhaler use: a call for improved clinician and patient education. Respir Care 2005; 50: 1360 – 74; discussion 74-5.

108.Basheti I.A., Reddel H.K., Armour C.L., Bosnic-Anticevich S.Z. Improved asthma outcomes with a simple inhaler technique intervention by community pharmacists. J Allergy Clin Immunol 2007;

119:1537 – 8.

109.Honkoop P.J., Loymans R.J.B., Termeer E.H., Snoeck-Stroband J.B., Bakker M.J. et al. Asthma control cost-utility randomized trial evaluation (ACCURATE): the goals of asthma treatment. BMC Pulm Med. 2011; 11: 53.

110.Paediatric Respiratory Medicine ERS Handbook 1st Edition Editors Ernst Eber. Fabio Midulla 2013 European Respiratory Society 719P.

111.Abramson M.J., Puy R.M., Weiner J.M. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010: CD001186.

112.Tao L., Shi B., Shi G., Wan H. Efficacy of sublingual immunotherapy for allergic asthma: retrospective meta-analysis of randomized, double-blind and placebo-controlled trials. Clin Respir J 2014;

8:192-205.

113.Virchow J.C., Backer V., Kuna P. et al. Efficacy of a house dust mite sublingualallergen immunotherapy tablet in adults with allergic asthma: A randomized clinical trial. Jama 2016; 315: 1715 –